Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04613128 · ClinicalTrials.gov registry record
The PROMISE Pediatric Study 6 to 11 Years Old
A clinical trial of Cystic Fibrosis and Cystic Fibrosis in Children, sponsored by Nicole Hamblett.
- Active
- Registry status
- 180
- Enrollment target
- 20
- Study locations
NCT04613128 is a study of Cystic Fibrosis and Cystic Fibrosis in Children that is active but no longer recruiting, run by Nicole Hamblett. The registered enrollment target is 180 participants, roughly in line with the 178-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target. The trial reports 20 study locations across 17 states.
The verdict
NCT04613128, a study of Cystic Fibrosis and Cystic Fibrosis in Children, is active but no longer recruiting, sponsored by Nicole Hamblett.
- ACTIVE NOT RECRUITING
- Registry status
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a prospective, multi-center observational study. The study is designed to measure the clinical effectiveness of elexacaftor, tezacaftor and ivacaftor (ETI) triple combination therapy in children (6-11 years of old) with one or more copies of the F508del mutation, study the effects of ETI across a number of CF disease manifestations, and collect specimens for future research. Subjects in the study will have one "before ETI" visit within 30 days before initiation of the therapy and five "after ETI" visits over a 24-month follow-up period. Participants who have participated in the original PROMISE Pediatric Sub-Study have the option of participating in a long-term extension with annual visits performed at the 36- and 48-month timepoints. The durability of the clinical and biological changes in the PROMISE Pediatric Sub-Study can be assessed with extended follow-up, which would enable the sub-studies to consider potential clinical consequences of the biological or physiological effects being studied. This work will help to inform long term prognosis and feasibility of certain clinical trials outcomes for interventional studies and may be useful when considering research priorities in drug development. The duration of participation for each subject is 24 months (with an additional 24 months if participants agree to the optional long-term extension). NOTE: FDA has granted approval for elexacaftor, tezacaftor and ivacaftor in the 6-11 age group.
Conditions Studied
Study Locations (20)
Missouri
- Children's Mercy Kansas City - Kansas City
- Washington University School of Medicine - St Louis
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center - Cleveland
Wisconsin
- University of Wisconsin - Madison
- Children's Hospital of Wisconsin - Milwaukee
Alabama
- University of Alabama at Birmingham - Birmingham
California
- Stanford University Medical Center - Palo Alto
Colorado
- Children's Hospital Colorado - Aurora
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Indiana
- Riley Hospital for Children - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2026-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04613128
The ClinicalTrials.gov registry entry for NCT04613128 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 178-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target. The listed sponsor is Nicole Hamblett, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT04613128 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Missouri, Ohio, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04613128 about?
NCT04613128 is a clinical study titled "The PROMISE Pediatric Study 6 to 11 Years Old". This is a prospective, multi-center observational study. The study is designed to measure the clinical effectiveness of elexacaftor, tezacaftor and ivacaftor (ETI) triple combination therapy in children (6-11 years of old) with one or more copies of the F508del mutation, study the effects of ETI acr...
What is the current status of trial NCT04613128?
This trial is currently active not recruiting. The enrollment target is 180 participants. The study started on 2021-06-11. Estimated completion is 2026-01-31.
What conditions does trial NCT04613128 study?
This clinical trial studies the following conditions: Cystic Fibrosis, Cystic Fibrosis in Children.
Who is sponsoring clinical trial NCT04613128?
This trial is sponsored by Nicole Hamblett, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04613128 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
RECRUITING
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Genetics of Insulin and Incretins in Cystic Fibrosis
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.